[1]袁嘉,全建峰,王文,等.健脾补肾方对Lewis肺癌荷瘤小鼠PD-1、PD-L1表达及Th1/Th2平衡的影响[J].陕西中医,2025,46(8):1042-1047.[doi:DOI:10.3969/j.issn.1000-7369.2025.08.006]
　YUAN Jia,QUAN Jianfeng,WANG Wen,et al.Effects of Jianpi Bushen formula on PD-1,PD-L1 expression and Th1/Th2 balance in Lewis lung carcinoma-bearing mice[J].,2025,46(8):1042-1047.[doi:DOI:10.3969/j.issn.1000-7369.2025.08.006]
点击复制

健脾补肾方对Lewis肺癌荷瘤小鼠PD-1、PD-L1表达及Th1/Th2平衡的影响

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年8期
页码:
1042-1047
栏目:
基础研究
出版日期:
2025-08-05

文章信息/Info

Title:
Effects of Jianpi Bushen formula on PD-1,PD-L1 expression and Th1/Th2 balance in Lewis lung carcinoma-bearing mice
作者:
袁嘉1; 全建峰2; 王文3; 王震1; 王希胜2; 康超4
（1.陕西中医药大学，陕西 咸阳 712046；2.陕西中医药大学附属医院，陕西 咸阳 712000；3.商洛市中医医院，陕西 商洛 726000；4.陕西省中医医院，陕西 西安 710003）
Author(s):
YUAN Jia1; QUAN Jianfeng2; WANG Wen3; WANG Zhen1; WANG Xisheng2; KANG Chao4
（1.Shaanxi University of Chinese Medicine,Xianyang 712046,China;2.Affiliated Hospital of Shaanxi University of Chinese Medicine,Xianyang 712000,China;3.Shangluo Traditional Chinese Medicine Hospital,Shangluo 726000,China;4.Shaanxi Academy of Traditional Chinese Medicine,Xi’an 710003,China）
关键词:
肺癌; 健脾补肾方; PD-1/PD-L1通路; Th1/Th2平衡; 免疫调节
Keywords:
Lung cancer; Jianpi Bushen formula; PD-1/PD-L1 pathway; Th1/Th2 balance; Immunomodulation
分类号:
R 734.2
DOI:
DOI:10.3969/j.issn.1000-7369.2025.08.006
文献标志码:
A
摘要:
目的：探讨健脾补肾方对Lewis肺癌荷瘤小鼠肿瘤免疫微环境程序性死亡受体-1（PD-1）/细胞程序性死亡-配体1（PD-L1）通路及相关免疫调节因子的调控作用。方法：通过Lewis肺癌细胞皮下接种构建C57BL/6J小鼠荷瘤模型，按随机数字表法将小鼠分为模型组、健脾补肾方低剂量组、中剂量组、高剂量组、化疗组及联合组，每组10只；各组小鼠给予相应处理，连续治疗14 d。处死后剥离瘤组织，测定抑瘤率；Western blot检测脾脏PD-1及PD-L1蛋白表达；ELISA检测脾脏组织Th1/Th2型细胞因子（IFN-γ、IL-2、IL-10、IL-4）水平。结果：健脾补肾方中剂量组、高剂量组、化疗组及联合组能够抑制肺癌移植瘤生长,抑瘤率分别是17.15%、29.76%、53.74%、55.14%；健脾补肾方各剂量组及联合组可显著抑制PD-1、PD-L1蛋白表达，其中以高剂量组效果最佳；健脾补肾方各剂量组及联合组Th1型细胞因子（IL-2、IFN-γ）浓度较模型组显著升高，Th2型细胞因子（IL-4、IL-10）浓度较模型组显著降低，以高剂量组效果最佳。结论：健脾补肾方可改善肺癌荷瘤小鼠的生存状态，对肺癌移植瘤的生长有一定抑制作用，机制可能与降低肿瘤微环境PD-1、PD-L1表达，升高IFN-γ、IL-2水平，降低IL-4、IL-10水平，改善Th1/Th2失衡有关。
Abstract:
Objective:To investigate the regulatory effects of Jianpi Bushen formula (JPBSF) on the programmed death receptor-1 (PD-1)/programmed death ligand 1 (PD-L1) pathway and immune-related cytokines in the tumor microenvironment of Lewis lung carcinoma (LLC)-bearing mice.Methods:An LLC subcutaneous xenograft model was established in C57BL/6J mice.The mice were divided into the model group,the JPBSF low-dose group，the JPBSF medium-dose group，the JPBSF high-dose group，the chemotherapy group and the combined group according to the random number table method,with 10 mice in each group.Mice in each group were given corresponding treatments and were continuously treated for 14 days.Interventions lasted 14 days.Tumor inhibition rates were calculated post-euthanasia.Western blot was used to detect the protein expressions of PD-1 and PD-L1 in the spleen.ELISA was used to detect the levels of Th1/Th2 cytokines (IFN-γ,IL-2,IL-10,IL-4) in spleen tissues.Results:The medium-dose group,high-dose group,chemotherapy group and combined group could inhibit the growth of lung cancer transplanted tumors,and the tumor inhibition rates were 17.15%,29.76%,53.74% and 55.14% respectively.JPBSF each dose group and the combined group can significantly inhibit the protein expressions of PD-1 and PD-L1,among which the high-dose group has the best effect.The concentrations of Th1-type cytokines (IL-2,IFN-γ) in JPBSF each dose group and the combined group were significantly higher than those in the model group,while the concentrations of Th2-type cytokines (IL-4,IL-10) were significantly lower than those in the model group.The high-dose group had the best effect.Conclusion:The JPBSF can improve the survival status of lung cancer tumor-bearing mice and has a certain inhibitory effect on the growth of lung cancer transplanted tumors.The mechanism may be related to reducing the expression of PD-1 and PD-L1 in the tumor microenvironment,increasing the levels of IFN-γ and IL-2,reducing the levels of IL-4 and IL-10,and improving the Th1/Th2 imbalance.

参考文献/References:

[1]BADE B C,DELA C S.Lung cancer 2020:Epidemiology,etiology,and prevention[J].Clin Chest Med,2020,41(1):1-24.
[2]BUDISAN L,ZANOAGA O,BRAICU C,et al.Links between infections,lung cancer,and the immune system[J].Int J Mol Sci,2021,22(17):9394.
[3]WU Q,JIANG L,LI S C,et al.Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway[J].Acta Pharmacol Sin,2021,42(1):1-9.
[4]YI M,ZHENG X,NIU M,et al.Combination strategies with PD-1/PD-L1 blockade:Current advances and future directions[J].Mol Cancer,2022,21(1):28.
[5]ZHOU Y J,LI G,WANG J,et al.PD-L1:Expression regulation[J].Blood Sci,2023,5(2):77-91.
[6]ANICHINI A,PEROTTI V E,SGAMBELLURI F,et al.Immune escape mechanisms in non small cell lung cancer[J].Cancers (Basel),2020,12(12):3605.
[7]尧忠柳,王莘智,叶新萍,等.从“正气化邪”探析自身免疫病的病机及辨治[J].中医杂志,2024,65(10):1013-1018.
[8]吴心语,李和根.中医扶正治疗肺癌对免疫调节作用的研究进展[J].世界中西医结合杂志,2022,17(8):1691-1696.
[9]汪舒云,吴霖光缙,陈彬,等.扶正类中药调节肿瘤免疫抑制微环境的研究现状[J].世界科学技术-中医药现代化,2022,24(10):3862-3868.
[10]黄伟,王希胜.王希胜教授运用健脾补肾法治疗肺癌临床经验[J].现代中医药,2018,38(5):7-9,20.
[11]康超,谢英瑛,校利绒,等.健脾补肾汤联合GP方案治疗鳞状细胞肺癌33例[J].现代中医药，2013,33(6):13，57.
[12]康超.健脾补肾方对Lewis肺癌移植瘤小鼠K-ras和突变型P53蛋白表达的影响[D].咸阳:陕西中医药大学,2014.
[13]王军徽,肖萌,马功贤,等.非小细胞肺癌中医药治疗研究进展[J].陕西中医,2023,44(11):1663-1665.
[14]张星星,李泽庚.肺癌中医病因病机探讨[J].中华中医药杂志,2015,30(10):3447-3449.
[15]GUO H,LOU Y,HOU X,et al.A systematic review of the mechanism of action and potential medicinal value of codonopsis pilosula in diseases[J].Front Pharmacol,2024,15:1415147.
[16]DAI L,LIU Z,ZHOU W,et al.Sijunzi decoction,a classical Chinese herbal formula,improves fatigue symptoms with changes in gut microbiota in chronic fatigue syndrome:A randomized,double-blind,placebo-controlled,multi-center clinical trial[J].Phytomedicine,2024,129:155636.
[17]CHEN J M,YANG T T,CHENG T S,et al.Modified Sijunzi decoction can alleviate cisplatin-induced toxicity and prolong the survival time of cachectic mice by recovering muscle atrophy[J].Ethnopharmacol,2019,233:47-55.
[18]肖保国.六味地黄丸联合化疗治疗非小细胞肺癌近期疗效研究[J].陕西中医,2018,39(2):193-195.
[19]ZHANG Y,LOU Y,WANG J,et al.Research status and molecular mechanism of the traditional Chinese medicine and antitumor therapy combined strategy based on tumor microenvironment[J].Front Immunol,2021,11:609705.
[20]ZHAO S H,WANG W H,LIANG Y C,et al.Research progress of Baihe Gujin Decoction in the treatment of lung cancer[J].Cancer Manag Res,2024,16:347-359.
[21]詹雪,冯诗函,杨倩,等.健脾除痰解毒方通过PD-1/PD-L1通路平衡Th1/Th2漂移而增强Lewis肺癌小鼠免疫功能[J].中国病理生理杂志,2023,39(10):1823-1831.
[22]WANG K,CHEN Q,SHAO Y,et al.Anticancer activities of TCM and their active components against tumor metastasis[J].Biomed Pharmacother,2021,133:111044.
[23]梁乐乐,王鹏,刘俊霞,等.非小细胞肺癌组织中T细胞免疫球蛋白区黏蛋白-3、程序性死亡因子-1及程序性因子配体1的表达分析[J].陕西医学杂志,2021,50(10):1227-1230.
[24]GHOSH C,LUONG G,SUN Y.A snapshot of the PD-1/PD-L1 pathway[J].J Cancer,2021,12(9):2735-2746.
[25]STIRLING E R,BRONSON S M,MACKERT J D,et al.Metabolic implications of immune checkpoint proteins in cancer[J].Cells,2022,11(1):179.
[26]LIU M,LI C,QU J,et al.Baicalein enhances immune response in TNBC by inhibiting leptin expression of adipocytes[J].Cancer Sci,2023,114(10):3834-3847.
[27]PRINCIPE D R,KAMATH S D,KORC M,et al.The immune modifying effects of chemotherapy and advances in chemo-immunotherapy[J].Pharmacol Ther,2022,236:108111.
[28]LUO M,FU L.The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis:Some chemotherapeutical drugs may finally work through immune response[J].Oncotarget,2016,7(20):29794-29803.
[29]HU X,LUO B,WU Q,et al.Effects of dezocine and sufentanil on Th1/Th2 balance in breast cancer patients undergoing surgery[J].Drug Des Devel Ther,2021,15:4925-4938.
[30]ZHAO X,LIU J,GE S,et al.Saikosaponin a inhibits breast cancer by regulating Th1/Th2 balance[J].Front Pharmacol,2019,10:624.
[31]BASU A,RAMAMOORTHI G,ALBERT G,et al.Differentiation and regulation of TH cells:A balancing act for cancer immunotherapy[J].Front Immunol,2021,12:669474.
[32]ZHANG W,PAN Y,GOU P,et al.Effect of xanthohumol on Th1/Th2 balance in a breast cancer mouse model[J].Oncol Rep,2018,39(1):280-288.
[33]LI B,LUO Y,ZHOU Y,et al.Role of sanguinarine in regulating immunosuppression in a Lewis lung cancer mouse model[J].Int Immunopharmacol,2022,110:108964.
[34]李津津,杨金颖,孙芳芳,等.黄芪多糖对Lewis荷瘤小鼠PD-1/PD-L1表达的影响[J].天津药学,2022,34(5)：9-13，37．
[35]KURESHI C T,DOUGAN S K.Cytokines in cancer[J].Cancer Cell,2025,43(1):15-35.

相似文献/References:

[1]刘海涛 ,衣秀秀,田建辉△.肺癌中西医抗凝治疗研究进展*[J].陕西中医,2020,(1):127.
[2]邵翠丽,周晋华△,杨勤军,等.周晋华运用环磷酰胺联合中药紫杉治疗晚期肺癌经验*[J].陕西中医,2020,(2):223.
　SHAO Cuili,ZHOU Jinhua,YANG Qinjun,et al.ZHOU Jinhua treats advanced lung cancer with cyclophosphamide and purple shirt[J].,2020,(8):223.
[3]汪 莉,杜红旭,周正国,等.攻癌固真汤联合吉非替尼治疗肺癌气虚血瘀证疗效及对患者血流状态的影响[J].陕西中医,2021,(3):338.[doi:DOI:10.3969/j.issn.1000-7369.2020.03.017]
　WANG Li,DU Hongxu,ZHOU Zhengguo,et al.Clinical effect of Gong'ai Guzhen decoction combined with gefitinib in treating lung cancer with Qixu Xueyu syndrome and affect blood flow state[J].,2021,(8):338.[doi:DOI:10.3969/j.issn.1000-7369.2020.03.017]
[4]郑 茜,刘远婷,丁甜甜,等.消积抑癌方对Lewis肺癌荷瘤小鼠MMP-2的影响[J].陕西中医,2021,(7):844.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.007]
　ZHENG Qian,LIU Yuanting,DING Tiantian,et al.Effect of Xiaoji Yi'ai recipe on MMP-2 in Lewis lung cancer bearing mice[J].,2021,(8):844.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.007]
[5]刘文佳,刘宗凯,初晓苏,等.山慈菇-王不留行干预肺癌向骨转移过程生物信息学作用机制[J].陕西中医,2021,(9):1302.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.041]
[6]杨 昕,李和根.肺癌辨证分型研究进展[J].陕西中医,2021,(9):1313.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.043]
　YANG Xin,LI Hegen.Progress in syndrome differentiation of lung cancer[J].,2021,(8):1313.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.043]
[7]李 健,贾 瑞,王 超,等.健脾益气汤联合化疗对肺癌术后患者免疫功能的影响[J].陕西中医,2023,(4):459.[doi:DOI:10.3969/j.issn.1000-7369.2023.04.011]
　LI Jian,JIA Rui,WANG Chao,et al.Effect of Jianpi Yiqi decoction combined with chemotherapy on immune function in patients with lung cancer after surgery[J].,2023,(8):459.[doi:DOI:10.3969/j.issn.1000-7369.2023.04.011]
[8]宁永波,王雅兴,陈香颖,等.名中医王瑞平“期证相合”理论在肺癌术后研究肿瘤微环境经验[J].陕西中医,2023,(10):1448.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.026]
　NING Yongbo,WANG Yaxing,CHEN Xiangying,et al.Wang Ruiping's theory of “phase correspondence” in postoperative lung cancer patients[J].,2023,(8):1448.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.026]
[9]张 尤,陈 炜.名中医韩明向基于“一本四证”论治肺癌经验[J].陕西中医,2023,(12):1788.[doi:DOI:10.3969/j.issn.1000-7369.2023.12.027]
[10]陈香颖,宁永波,王雅兴,等.名中医王瑞平运用“培土生金法”治疗肺癌经验[J].陕西中医,2024,(4):536.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.023]
　CHEN Xiangying,NING Yongbo,WANG Yaxing,et al.Experience of professor Wang Ruiping using “tonifying the spleen and replenishing the lung” to treat lung cancer[J].,2024,(8):536.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.023]

备注/Memo

备注/Memo:
陕西省自然科学基础研究计划项目（2023-JC-YB-803）
更新日期/Last Update: 2025-08-08